{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:52:19Z","timestamp":1792212739278,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01543-6","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:34:51Z","timestamp":1782707691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of patients with higher-risk myelodysplastic syndromes\/neoplasms treated with hypomethylating agents + venetoclax\u2014an analysis from the International Consortium for MDS (icMDS) VALIDATE database"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-5125","authenticated-orcid":false,"given":"Tariq","family":"Kewan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-8829","authenticated-orcid":false,"given":"Luca","family":"Lanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7089-2643","authenticated-orcid":false,"given":"Tulika","family":"Rudra Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Stempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla H.","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-8248","authenticated-orcid":false,"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata Sonia","family":"Chandhok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine N.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Bidikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7393-861X","authenticated-orcid":false,"given":"Benjamin","family":"Rolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amyah C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-5019","authenticated-orcid":false,"given":"Maria L.","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9804","authenticated-orcid":false,"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7912","authenticated-orcid":false,"given":"Yasmin","family":"Abaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclynn","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-090X","authenticated-orcid":false,"given":"Anoop","family":"Enjeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Al-Rabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-3056","authenticated-orcid":false,"given":"Devendra","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6779","authenticated-orcid":false,"given":"Maria","family":"Diez-Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-078X","authenticated-orcid":false,"given":"David","family":"Valcarcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5049","authenticated-orcid":false,"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-0186","authenticated-orcid":false,"given":"Ioannis","family":"Kotsianidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-9424","authenticated-orcid":false,"given":"Vassiliki","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Consagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-5374","authenticated-orcid":false,"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-0992","authenticated-orcid":false,"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Giovanni","family":"Della Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u201332.","journal-title":"Lancet Oncol"},{"key":"1543_CR2","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794\u2013803.","journal-title":"Cancer"},{"key":"1543_CR3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11:e15\u201326.","journal-title":"Lancet Haematol"},{"key":"1543_CR4","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/leu.2015.115","volume":"29","author":"T Bernal","year":"2015","unstructured":"Bernal T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, Luno E, Nomdedeu B, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29:1875\u201381.","journal-title":"Leukemia"},{"key":"1543_CR5","doi-asserted-by":"crossref","unstructured":"Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, et al. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study(dagger). Leuk Lymphoma. 2019:1\u201310.","DOI":"10.1080\/10428194.2019.1703970"},{"key":"1543_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","volume":"131","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:818\u201321.","journal-title":"Blood"},{"key":"1543_CR7","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","volume":"6","author":"L Ad\u00e8s","year":"2022","unstructured":"Ad\u00e8s L, Girshova L, Doronin VA, D\u00edez-Campelo M, Valc\u00e1rcel D, Kambhampati S, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022;6:5132\u201345.","journal-title":"Blood Adv"},{"key":"1543_CR8","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","volume":"35","author":"MA Sekeres","year":"2017","unstructured":"Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35:2745\u201353.","journal-title":"J Clin Oncol"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Ando K, Rauzy O, Turgut M, Wang M-C, Cairoli R, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024;11:e38\u201350.","journal-title":"Lancet Haematol"},{"key":"1543_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.2025029727","volume":"147","author":"M Stahl","year":"2026","unstructured":"Stahl M, Zeidan AM. The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. Blood. 2026;147:811\u201320.","journal-title":"Blood"},{"key":"1543_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2025","unstructured":"Garcia JS, Platzbecker U, Odenike O, Fleming S, Fong CY, Borate U, et al. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025;145:1126\u201335.","journal-title":"Blood"},{"key":"1543_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1543_CR13","doi-asserted-by":"publisher","first-page":"S644","DOI":"10.1016\/S2152-2650(25)02083-X","volume":"25","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P, Roboz GJ, Fong CY, Hus M, et al. MDS-1497: primary analysis of the randomized, phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2025;25:S644\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1543_CR14","first-page":"2047","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ad\u00e8s L, Borate U, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047\u201361.","journal-title":"Blood"},{"key":"1543_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"1543_CR16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood"},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1543_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/biom.12384","volume":"72","author":"L Zhao","year":"2016","unstructured":"Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72:215\u201321.","journal-title":"Biometrics"},{"key":"1543_CR19","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","volume":"325","author":"K Yadav","year":"2021","unstructured":"Yadav K, Lewis RJ. Immortal time bias in observational studies. JAMA. 2021;325:686\u20137.","journal-title":"JAMA"},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389\u2013430.","journal-title":"Stat Med"},{"key":"1543_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"4","author":"U Dafni","year":"2011","unstructured":"Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363\u201371.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1543_CR23","first-page":"2159","volume":"111","author":"M Aldapt","year":"2026","unstructured":"Aldapt M, Wang Y-H, Shah KJ, Kettani M, Foran J, Kharfan-Dabaja M. Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53 -mutated myelodysplastic syndromes. Haematologica. 2026;111:2159\u201363.","journal-title":"Haematologica"},{"key":"1543_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1543_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","volume":"16","author":"W Bahaj","year":"2023","unstructured":"Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J Hematol Oncol. 2023;16:91.","journal-title":"J Hematol Oncol"},{"key":"1543_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood-2025-235","volume":"146","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P, Roboz G, Fong CY, Hus M, et al. Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-na\u00efve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS). Blood. 2025;146:235.","journal-title":"Blood"},{"key":"1543_CR27","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1002\/ajh.26539","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, et al. Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. Am J Hematol. 2022;97:E214\u201316.","journal-title":"Am J Hematol"},{"key":"1543_CR28","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1543_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0081-8","volume":"8","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. Blood Cancer J. 2018;8:55.","journal-title":"Blood Cancer J"},{"key":"1543_CR30","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1200\/JCO.23.02175","volume":"42","author":"CA Tentori","year":"2024","unstructured":"Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, et al. Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes. J Clin Oncol. 2024;42:2873\u201386.","journal-title":"J Clin Oncol"},{"key":"1543_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2025-239","volume":"146","author":"GS Guru Murthy","year":"2025","unstructured":"Guru Murthy GS, Abaza Y, Ball S, Abboud R, Haddadin M, Feld J, et al. Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes. Blood. 2025;146:239.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01543-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:03:53Z","timestamp":1789427033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01543-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following conflict of interests: AED: Sobi: Consultancy; Novartis: Membership on an entity\u2019s Board of Directors or advisory committees; Geron: Membership on an entity\u2019s Board of Directors or advisory committees; Caribou: Membership on an entity\u2019s Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy; Appellis: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees. Celgene\/BMS, Agios, and Novartis: Advisory boards and\/or consultancy; Geron, Servier, Keros, Shuattuck labs, and Celgene\/BMS: Clinical trial committees or DSMB. MAS: Geron: Membership on an entity\u2019s Board of Directors or advisory committees; Kurome: Consultancy, Current holder of\n                      stock options\n                      in a privately-held company; Novartis: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees. GLU: Incyte: consultancy; Geron: consultancy; Syndax: consultancy; Autolus: consultancy; Vironexis: consultancy; HEC: Agios: Consultancy, Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Other: Travel, Accommodations, Expenses, Speakers Bureau; Takeda: Other; Genentech: Consultancy; Daiichi: Consultancy; Celgene: Research Funding; Syndax: Other: DSMB; Astex Pharmaceuticals: Other; AbbVie\n                      :\n                      Other; Stemline Therapeutics: Consultancy, Speakers Bureau; Novartis: Consultancy, Other: Travel, Accommodations, Expenses, Speakers Bureau. PD: Abbvie: Consultancy, Other: Advisory role; BMS: Consultancy, Other: Advisory role, Research Funding; Janssen Research & Development: Research Funding; Servier: Consultancy, Other: Advisory role; Janssen Pharmaceuticals: Current Employment. Syndax: Consultancy; Kura Oncology: Consultancy. EAG: Alexion Pharmaceuticals\/AstraZeneca Rare Disease: Consultancy, Research Funding; Apellis Pharmaceuticals: Consultancy, Research Funding; Blueprint Medicines, Inc: Research Funding; Bristol-Myers Squibb: Consultancy\/Research Funding; Celldex Therapeutics: Research Funding; Cogent Biosciences: Consultancy; Curio Science: Honoraria; Geron Inc.: Consultancy; MediCom Worldwide, Inc.: Honoraria; MedscapeLIVE: Honoraria; NextCure, Inc: Research Funding; Novartis: Consultancy, Research Funding; Pfizer Inc: Consultancy; Refined Oncology: Consultancy; Servier Pharmaceuticals: Consultancy; Taiho Oncology\/Astex Pharmaceuticals: Consultancy\/Research Funding; Vera and Joseph Dresner Foundation: Membership on an entity\u2019s Board of Directors or advisory committees. VJHemeOnc: Honoraria. EMS: Calithera: Consultancy; Daiichi: Consultancy; Foghorn: Consultancy; Servier: Consultancy; CTI Biopharma: Consultancy; Menarini: Consultancy; Genentech: Consultancy; Genesis: Consultancy; Syndax: Consultancy; OnCusp: Consultancy; Abbvie: Consultancy; Neoleukin: Consultancy; Jazz: Consultancy; Bristol Myers Squib: Consultancy, Research Funding; Agios: Consultancy; Novartis: Consultancy; Gilead: Consultancy; Eisai: Research Funding; Janssen: Consultancy; PinotBio: Consultancy; Aptose: Consultancy; Syros: Consultancy; Astellas: Consultancy; Ono Pharma: Consultancy; Blueprint: Consultancy. AMB: Agios: Consultancy, Research Funding; AstraZeneca: Research Funding; Celgene\/BMS\n                      :\n                      Consultancy, Research Funding; Gilead: Consultancy; Taiho: Consultancy; Novartis: Consultancy, Research Funding; Janssen: Research Funding; Keros Therapeutics: Consultancy; Takeda: Consultancy; Acceleron: Consultancy; GSK: Research Funding. CM: Syndax: Advisory board; Kura Oncology: Safety monitoring committee. RMS: Bristol Myers Squibb: Consultancy; Cardinal Health: Consultancy, Honoraria; Curio Science: Consultancy; Geron: Consultancy, Honoraria; Gilead Sciences: Consultancy, Honoraria; Kura Oncology: Consultancy; Rigel: Consultancy; Servier: Consultancy; Syndax Pharmaceuticals: Consultancy; TScan Therapeutics: Consultancy. JFZ: AbbVie: Consultancy, Research Funding; Akesobio: Research funding; Aptevo: Research funding; Arog: Research Funding; Ascentage: Research funding; Astellas: Consultancy; AstraZeneca: Consultancy, Research Funding; Auron: Research Funding; Crossbow Therapeutics: Consultancy; Daiichi Sankyo: Consultancy, Research Funding; Faron: Research Funding; Foghorn: Consultancy; Genentech: Consultancy; Genmab: Consultancy; Geron: Consultancy; Ipsen: Consultancy; Jazz: Consultancy, Research Funding; Johnson & Johnson: Consultancy; Kura Oncology: Consultancy, Research Funding; Lin Biosciences: Research Funding; Loxo: Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding; Relmada Therapeutics: Consultancy; Rigel: Consultancy; Sellas: Consultancy, Research Funding; Servier: Consultancy; Shattuck Labs: Consultancy, Research Funding; Stemline: Research Funding; Sumitomo Pharma: Consultancy, Research Funding; Syndax: Consultancy; Zentalis: Research Funding. MRS: Karyopharm Therapeutics Inc.: Consultancy, Current equity holder in publicly-traded company; Empath Biosciences: Current equity holder in publicly-traded company; Incyte Corporation: Research Funding; Sierra Oncology, Inc.: Consultancy; Taiho: Research funding and travel costs; ALX Oncology: Research Funding; AbbVie Inc.: Consultancy; Boehringer Ingelheim: Patents & Royalties; TG Therapeutics, Inc.: Research Funding; Takeda Pharmaceutical Company: Consultancy, Research Funding; Ryvu Therapeutics: Consultancy, Current equity holder in publicly-traded company; Novartis: Consultancy; Geron Corporation: Consultancy; Forma Therapeutics Inc.: Consultancy, Consultancy; Bristol Myers Squibb: Membership on an entity\u2019s Board of Directors or advisory committees; CTI BioPharma Corp.: Consultancy. CNL: Azurity: Advisory board. GJR: Agios: Consultancy; Actinium: Consultancy; Amgen: Consultancy; Astellas: Consultancy; AstraZeneca: Consultancy; Bristol Myers Squibb: Consultancy; Celgene: Consultancy; Caribou Biosciences: Consultancy; Daiichi Sankyo: Consultancy; Ellipses Pharma: Consultancy; Geron: Consultancy; Glycomimetics: Consultancy; Jazz Pharmaceuticals: Consultancy; MEI: Consultancy; Mesoblast: Consultancy; Molecular Partners: Consultancy; Morphosys: Consultancy; Oncoprecision: Consultancy; Oncoverity: Consultancy; AbbVie: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Rigel: Consultancy; Roche: Consultancy; Syndax: Consultancy; Blueprint: Consultancy; Jasper Pharmaceuticals: Consultancy; Bluebird bio: Consultancy; GlaxoSmithKline: Consultancy; Janssen: Consultancy and research support. Funding; Takeda: Consultancy. ESW: Gilead: Consultancy; GlaxoSmithKline: Consultancy; Jazz: Consultancy; Kite: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; PharmaEssentia: Consultancy; Takeda: Consultancy; Dava oncology: Speakers Bureau; Kura Oncology: Speakers Bureau; BMS: Consultancy; Astellas: Consultancy, Speakers Bureau; Abbvie: Consultancy. ZX: Novartis: Speakers Bureau; Moffitt Cancer Center: Current Employment. JPM: Regeneron: Consultancy, Honoraria; Alexion: Membership on an entity\u2019s Board of Directors or advisory committees; Novartis: Honoraria, Speakers Bureau; Omeros: Consultancy. DS: Aprea, Jazz: Research Funding; AbbVie, Affimed Gmbh, Gilead, Incyte, Intellisphere, LLC, Molecular Partners AG, PGEN Therapeutics, Inc., Takeda, Zentalis; Advisory board for AvenCell, BlueBird Bio, BMS, Intellia, Jasper Therapeutics, Kite, Magenta Therapeutics, NKARTA, Novartis, Orbita: Consultancy. AA-K: Novartis: Research funding to institution, consultancy; Astex: Research funding to institution; ALX Oncology: Research funding to institution; BMS: Research funding to institution; Aprea: Research funding to institution; H3B\/Hemavant: Research funding to institution, Celgene: Research funding to institution. AE: Otsuka: Consultancy, honoraria, research funding to institution; Servier: Consultancy; Jazz: Consultancy; RaceOncology: Consultancy, honoraria; Amgen: Consultancy; AbbVie: Consultancy. YFM: Honoraria\/consulting fees from BMS, Kura Oncology, BluePrint Medicines, Geron, OncLive and MD Education, VJHemOnc and Medscape Live. Advisory boards and received honoraria from Stemline Therapeutics, Blueprint Medicines, Taiho Oncology, SOBI, Rigel Pharmaceuticals, Geron, Cogent Biosciences. Received travel reimbursement from MD Education. YA: Consultancy, Honoraria: Astellas, Bristol Myers Squibb, Daiichi Sankyo, Geron, KiTE, Pfizer, Rigel, and Servier. Research funding to institution: AbbVie, ALX Oncology, Biomea, Biosight, Curis, and Novartis. TB: Honoraria from Amgen, Ascentage, Syndax, Geron, Takeda. Research funding from Takeda, Amgen. TH: MLL Munich Leukemia Laboratory: equity ownership. IK: Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria; Novartis: Consultancy, Research Funding. VP: Research Support \/PI : Celgene, Janssen, Abvie; Honoraria\/Advisory Board: Genesis Pharma, Janssen, Roche, Servier, Abvie, Novartis, Gilead, BMS, Astra Zeneca, GSK, Amgen, Sobi, Pfizer. CH: MLL Munich Leukemia Laboratory: equity ownership. MS: Kymera: Membership on an entity\u2019s Board of Directors or advisory committees; Rigel: Membership on an entity\u2019s Board of Directors or advisory committees; Curis Oncology: Other: GME activity; Clinical care options: Other: GME activity; GSK: Membership on an entity\u2019s Board of Directors or advisory committees; Novartis: Membership on an entity\u2019s Board of Directors or advisory committees, Other: GME activity; Haymarket Media: Other: GME activity; Boston Consulting: Consultancy; Sierra Oncology: Membership on an entity\u2019s Board of Directors or advisory committees; Dedham group: Consultancy. MGDP: Bristol Myers Squibb: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees. RSK: Geron: Consultancy; BMS: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; AbbVie, CTI biopharma, Jazz, Pharma Essentia, Servio: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Speakers Bureau; Rigel, Taiho, DSI: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Novartis: Membership on an entity\u2019s Board of Directors or advisory committees. AMZ: Incyte: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Boehringer-Ingelheim: Consultancy, Honoraria; Schr\u00f6dinger: Consultancy, Honoraria; Celgene\/BMS: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Syros: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Zentalis: Consultancy, Honoraria; Tyme: Consultancy, Honoraria; Astex: Research Funding; Shattuck Labs: Research Funding; AbbVie: Consultancy, Honoraria; Lox Oncology: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Mendus: Consultancy, Honoraria; Foran: Consultancy, Research Funding; Otsuka: Consultancy, Honoraria; BioCryst: Consultancy, Honoraria; ALX Oncology: Consultancy, Honoraria; BeyondSpring: Consultancy, Honoraria; Chiesi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Kura: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Syndax: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Notable: Consultancy, Honoraria; Taiho: Consultancy, Honoraria; Geron: Consultancy, Honoraria; Orum: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"155"}}